The Patent Finder
BD

Black Diamond Therapeutics, Inc.

First filing 2020
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Four patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2039. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2039
Next term end
4
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2043.
US 11,034,672 Tyrosine Kinase Inhibitor Compositions, Methods of Making and Methods of Use Oct 2, 2039
US 12,741,976 Quinoxaline Derivatives and Uses Thereof Dec 16, 2042
US 12,435,046 Alkynyl Quinazoline Compounds Jan 6, 2043
US 12,714,713 Method of Treating Cancers with Alkyne Substituted Quinazoline Derivatives Jan 6, 2043
20262031203620412043
7 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 4 of 4

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,034,672Tyrosine Kinase Inhibitor Compositions, Methods of Making and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,741,976Quinoxaline Derivatives and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 12,435,046Alkynyl Quinazoline Compounds
In force
 · High confidence
In forceHigh confidence
US 12,714,713Method of Treating Cancers with Alkyne Substituted Quinazoline Derivatives
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 7 applications pending · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited